Immunotech Biopharm Ltd Ordinary Shares 06978
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HK$2.45
- Day Range
- HK$2.40–2.63
- 52-Week Range
- HK$2.21–5.00
- Bid/Ask
- HK$2.39 / HK$2.60
- Market Cap
- HK$1.32 Bil
- Volume/Avg
- 386,000 / 106,288
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 202
- Website
- https://www.eaal.net
Comparables
Valuation
|
Metric
|
06978
|
09966
|
09688
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 1.78 | 3.22 |
Price/Sales | — | 10.60 | 6.94 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
06978
|
09966
|
09688
|
|---|---|---|---|
Quick Ratio | 0.36 | 4.42 | 2.81 |
Current Ratio | 0.38 | 4.61 | 3.46 |
Interest Coverage | −37.83 | −25.20 | — |
Quick Ratio
06978
09966
09688
Profitability
|
Metric
|
06978
|
09966
|
09688
|
|---|---|---|---|
Return on Assets (Normalized) | −24.06% | −8.50% | −22.08% |
Return on Equity (Normalized) | −267.27% | −11.48% | −27.96% |
Return on Invested Capital (Normalized) | −30.83% | −12.12% | −31.10% |
Return on Assets
06978
09966
09688
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Jtpcxspxv | Bpzj | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Bjnlvpw | Dzlswy | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pjxsdprs | Gbzpq | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mjmcvcv | Glwfr | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Vlsldsxk | Rzfn | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Wqtdvcnn | Mnzvw | $28.1 Bil | |||
| Moderna Inc
MRNA
| Flxnmzxx | Cxsm | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Nlxddkkds | Qtnh | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hbrxshxp | Lhszwk | $13.4 Bil | |||
| Incyte Corp
INCY
| Kpxtfwhp | Spdpzql | $12.7 Bil |
United States